A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease
Status:
Recruiting
Trial end date:
2023-09-29
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of single and
multiple doses of BIIB094 administered via intrathecal (IT) injection to participants with
Parkinson's Disease (PD). The secondary objective of this study is to evaluate the
pharmacokinetic (PK) profile of BIIB094.The study is open for PD patients with verified
presence or absence of variations in the leucine-rich repeated kinase 2 (LRRK2) gene, but
also for patients without any verified PD-related genetic variant.